Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 12/20 | 0.51 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.44 |
| ▸ | BRD2 | P25440 | 7/20 | 0.43 |
| ▸ | BRD3 | Q15059 | 6/20 | 0.43 |
| ▸ | ERN1 | O75460 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.37 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.37 |
| ▸ | AR | P10275 | 1/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18249987 | 0.86 | NSD3 (0.50) | BRD4NSD3BRD2BRD3ERN1 | |
| SCHEMBL18249960 | 0.86 | BRD4 (0.49) | BRD4NSD3BRD2BRD3ERN1 | |
| SCHEMBL11985075 | 0.84 | BRD4 (0.61) | BRD4BRD2BRD3CYP3A4CYP2C9 | |
| SCHEMBL18249909 | 0.84 | BRD4 (0.47) | BRD4NSD3BRD2BRD3ERN1 | |
| SCHEMBL1905359 | 0.79 | BRD4 (0.56) | BRD4BRD2BRD3ERN1CYP3A4 | |
| SCHEMBL16619466 | 0.77 | BRD4 (0.48) | BRD4BRD2BRD3CYP3A4CYP2C9 | |
| SCHEMBL11980665 | 0.76 | BRD4 (0.46) | BRD4BRD2BRD3ERN1CYP3A4 | |
| SCHEMBL15960727 | 0.75 | TLR8 (0.45) | CYP3A4CYP1A2CYP2C9CYP2C19HSD17B10 | |
| SCHEMBL11980664 | 0.73 | ERN1 (0.47) | BRD4BRD2BRD3ERN1CYP3A4 | |
| SCHEMBL21136920 | 0.72 | TLR8 (0.46) | CYP3A4TLR8LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150133436-A1 | Bromodomain Inhibitors For Treating Autoimmune And Inflammatory Diseases | GLAXOSMITHKLINE LLC | 2015-05-14 | — | — | US | disclosed |
| US-20140243321-A1 | BIOORTHOGONAL MONOMERS CAPABLE OF DIMERIZING AND TARGETING BROMODOMAINS, AND METHODS OF USING SAME | COFERON, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-20140243322-A1 | BIVALENT BROMODOMAIN LIGANDS, AND METHODS OF USING SAME | COFERON, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-20140243286-A1 | BROMODOMAIN LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME | COFERON, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-8557984-B2 | Imidazo [4, 5-C] quinoline derivatives as bromodomain inhibitors | GLAXOSMITHKLINE LLC (US) | 2013-10-15 | — | — | US | disclosed |
| US-20120232074-A1 | Imidazo [4, 5-C] Quinoline Derivatives As Bromodomain Inhibitors | GLAXOSMITHKLINE LLC | 2012-09-13 | — | — | US | disclosed |
| US-20120208800-A1 | Bromodomain Inhibitors For Treating Autoimmune And Inflammatory Diseases | GLAXOSMITHKLINE LLC | 2012-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243322-A1 | BIVALENT BROMODOMAIN LIGANDS, AND METHODS OF USING SAME | BRDT, BRD2, BRD4 | BRD4 3/4885NSD3 128/4885BRD2 2/4885 |
| US-20120208800-A1 | Bromodomain Inhibitors For Treating Autoimmune And Inflammatory Diseases | BRD4, BRD3, BRPF3 | BRD4 1/4885NSD3 89/4885BRD2 4/4885 |
| US-20140243286-A1 | BROMODOMAIN LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME | BRDT, BRD4, BRD1 | BRD4 2/4885NSD3 780/4885BRD2 5/4885 |
| US-20150133436-A1 | Bromodomain Inhibitors For Treating Autoimmune And Inflammatory Diseases | BRD4, BRD3, BRPF3 | BRD4 1/4885NSD3 89/4885BRD2 4/4885 |
| US-20140243321-A1 | BIOORTHOGONAL MONOMERS CAPABLE OF DIMERIZING AND TARGETING BROMODOMAINS, AND METHODS OF USING SAME | BRDT, BRD4, BRD1 | BRD4 2/4885NSD3 1450/4885BRD2 5/4885 |
| US-20120232074-A1 | Imidazo [4, 5-C] Quinoline Derivatives As Bromodomain Inhibitors | BRD4, BRD3, BRPF3 | BRD4 1/4885NSD3 64/4885BRD2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.